Fibrocell Science Inc

Fibrocell Science — Technical Presentation (May 2017)

13 slides from Fibrocell Science's technical presentation, May 11, 2017

  1. Slide 1: Development of an Autologous Gene-Modified Cell Therapy for the Treatment of Linear Scleroderma

    Development of an Autologous Gene-Modified Cell Therapy for the Treatment of Linear Scleroderma Tathagata Chaudhuri,1 Scott Moncrief,1 Anna Malyala,2 John Maslowski,2 Darby L. Thomas1 1Intrexon Corporation, Germantown MD; 2Fibrocell, Exton PA Presented at the 20th Annual American Society of Gene and

  2. Slide 2: Forward-Looking Statements

    © 2017 Intrexon Corp. All rights reserved. 2 © 2017 Intrexon Corp. All rights reserved. Intrexon Corporation is sharing the following materials for informational purposes only. Such materials do not constitute an offer to sell or the solicitation of an offer to buy any securities of Intrexon. Any of

  3. Slide 3: Collaboration

    © 2017 Intrexon Corp. All rights reserved. 3 Collaboration

  4. Slide 4: FCX-013 for Linear Scleroderma

    © 2017 Intrexon Corp. All rights reserved. 4 FCX-013 for Linear Scleroderma • Localized scleroderma is characterized by excess collagen production resulting in skin fibrosis • Underlying tissues and muscle may also be affected which can impair growth in affected legs, arms or forehead in linear scle

  5. Slide 5: MMP1 and the RheoSwitch Therapeutic System

    © 2017 Intrexon Corp. All rights reserved. 5 • MMP1: matrix metalloproteinase 1 (interstitial collagenase) • zinc-dependent zymogen protease cleaves collagens of types I, II, and III • Expression of MMP1 controlled by the RheoSwitch Therapeutic System® (RTS®) • oral administration or withdrawal of a

  6. Slide 6: Proof-of-concept study: Bleomycin-induced scleroderma

    © 2017 Intrexon Corp. All rights reserved. 6 • Groups: 1. BLM-treated : HDF-RTS-MMP1 : oral excipient 2. BLM-treated : HDF-RTS-MMP1 : oral veledimex 3. BLM-treated : non-GM HDFs : oral veledimex 4. Saline : saline : oral veledimex • Female NOD/SCID mice, 5e5 cells in 100 µL • Endpoints: • Dermal and

  7. Slide 7: Representative histological images

    © 2017 Intrexon Corp. All rights reserved. 7 Representative histological images 4) Saline (no BLM) No cells Oral veledimex (normal skin) 1) Bleomycin HDF-RTS-MMP1 Oral excipient 2) Bleomycin HDF-RTS-MMP1 Oral veledimex (experimental) 3) Bleomycin Non-GM HDFs Oral veledimex (disease control)

  8. Slide 8: HDF-RTS-MMP1 Reduction of Dermal Thickness

    © 2017 Intrexon Corp. All rights reserved. 8 HDF-RTS-MMP1 Reduction of Dermal Thickness 0 50 100 150 200 250 1: Bleomycin HDF-RTS-MMP1 oral excipient 2: Bleomycin HDF-RTS-MMP1 oral veledimex 3: Bleomycin non-GM HDFs oral veledimex 4: saline (no BLM) no cells oral veledimex Mean D e rmal Th ickne ss,

  9. Slide 9: HDF-RTS-MMP1 Reduction of Sub-Dermal Muscle Thickness

    © 2017 Intrexon Corp. All rights reserved. 9 HDF-RTS-MMP1 Reduction of Sub-Dermal Muscle Thickness • Image analyses: 5 slides per mouse, 5 images per slide, means +/- SD presented • 10X magnification, 1 pixel = 0.8686 µm conversion 0 50 100 150 200 250 300 350 1: Bleomycin HDF-RTS-MMP1 oral excipien

  10. Slide 10: Systemic detection of MMP1

    © 2017 Intrexon Corp. All rights reserved. 10 Systemic detection of MMP1 • MesoScale Discovery assay of serum • LLOQ = 48 .8 pg/mL; LLOD = 22 pg/mL 0 500 1000 1500 2000 2500 3000 3500 1: Bleomycin HDF-RTS-MMP1 oral excipient 2: Bleomycin HDF-RTS-MMP1 oral veledimex 3: Bleomycin non-GM HDFs oral vele

  11. Slide 11: Pre-Clinical/IND-enabling development

    © 2017 Intrexon Corp. All rights reserved. 11 • Non-GLP toxicology / biodistribution / dose ranging study -- in data collection and analysis phase • Next step -- toxicology/pharmacology study • Engineering runs for manufacturing ongoing Pre-Clinical/IND-enabling development

  12. Slide 12: Summary

    © 2017 Intrexon Corp. All rights reserved. 12 • FCX-013: autologous dermal fibroblasts genetically-modified to express MMP1 under RTS® gene switch control • Initial proof-of-concept study demonstrated significant reduction in dermal and sub-dermal muscle thickness after intradermal injection of GM-H

  13. Slide 13: Acknowledgements

    © 2017 Intrexon Corp. All rights reserved. 13 Acknowledgements • Tathagata Chaudhuri, PhD • Scott Moncrief, PhD • Jacques Plummer • Rahim Johnson • Ernie Boyd • Anna Malyala, PhD • John Maslowski

Fibrocell Science — Technical Presentation (May 2017) on 6ix